الفهرس 
EPIDEMIOLOGYOnly 14 pages are availabe for public view
 |  | from | 221 |  |  |
| | | from | 221 | | |
Abstract
SUMMARY This study included 40 female patients with stage II, III triple negative breast cancer who presented and treated at Clinical Oncology and Nuclear Medicine Department, Tanta University Hospitals and Oncology Department of Health Insurance hospitals during the period from January 2011 to December 2015.The aim of the study is to compare between paclitaxel and doxorubicin versus paclitaxel and carboplatin as neoadjuvant chemotherapy in triple negative breast cancer as regard treatment response, survival rates and toxicity and to analyse different prognostic factors which may affect response and survival, with special emphasis on tumour infiltrating lymphocytes (TILs) and their immunophenotyping profile as a prognostic and predictive marker.Stromal tumour infiltrating lymphocytes (TILs) IHC score is the proportion of the area infiltrated by lymphocytes within the adjacent stroma of tumor, and classified the scores as low(<10 %), intermediate(10–40 %), and high (>40 %).Triple-negative breast cancer patients in this study were classified into two groups; group A:20 patients treated NAC with paclitaxel and doxorubicin and group B: 20 patients treated with NAC paclitaxel and carboplatin.There were no significant differences for patients characteristics between the two groups as regard age, performance, tumor size,lymph nodes, stage, lymphovascular invasion, multifocality, KI67 or
surgery.